Neuronetics (STIM) Common Equity (2017 - 2026)

Neuronetics (STIM) has 10 years of Common Equity data on file, last reported at $13.3 million in Q1 2026.

• On a quarterly basis, Common Equity fell 66.44% year-over-year to $13.3 million in Q1 2026; TTM through Mar 2026 was $13.3 million, a 66.44% decrease from a year earlier, with the FY2025 full-year figure at $26.2 million, down 17.48% from the prior year.
• Common Equity for Q1 2026 stood at $13.3 million, down from $26.2 million in the prior quarter.
• Over the last five years, Common Equity for STIM reached as high as $76.6 million in Q1 2022 and fell as low as $9.4 million in Q3 2024.
• Historically, Common Equity has averaged $38.7 million across 5 years, with a median of $34.2 million in 2023.
• Across the five-year window, Common Equity sank 75.27% in 2024 and soared 191.61% in 2025, its largest moves.
• Year by year, Common Equity stood at $57.1 million in 2022, then slumped by 40.08% to $34.2 million in 2023, then fell by 6.99% to $31.8 million in 2024, then retreated by 17.48% to $26.2 million in 2025, then slumped by 49.45% to $13.3 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $13.3 million in Q1 2026, $26.2 million in Q4 2025, and $27.4 million in Q3 2025.